Why Early Cancer Detection Matters ?

• Higher Survival Rates
  • When cancer is found early, it’s usually smaller and hasn’t spread.
  • For example, early-stage breast cancer has a 5-year survival rate above 90%, compared to less than 30% when detected late.
• Less Aggressive Treatment
  • Early cancers may be treated with surgery alone, instead of needing chemotherapy or radiation.
  • This means fewer side effects and better quality of life.
• Lower Costs
  • Treating cancer at an advanced stage is much more expensive. Early detection saves both lives and healthcare resources.
• More Options for Patients
  • At early stages, patients have more choices (surgery, targeted therapy, less invasive treatments).
  • At late stages, options become limited.

How MCED (Multi-Cancer Early Detection) Tests play a role ?

Multi-Cancer Early Detection (MCED) tests play a crucial role in cancer treatment by focusing on the earliest stages of the disease, often before symptoms appear. Their primary impact lies in shifting the paradigm from late-stage diagnosis to early-stage detection, which can significantly improve treatment outcomes.

Here’s a breakdown of how MCED tests can influence cancer treatment:

• Enabling Earlier Treatment: The most significant benefit is the potential to detect cancers at earlier, more treatable stages. Many cancers lack recommended screening tests and are typically diagnosed only after a patient becomes symptomatic, often when the cancer has already advanced and treatment options are limited. By detecting these cancers in asymptomatic individuals, MCED tests can allow for earlier intervention and a greater chance of successful and potentially curative treatment.
• Guiding Diagnostic Pathways: A positive MCED test does not diagnose cancer on its own. Instead, it provides a “cancer signal” and, in many cases, can predict the likely tissue of origin (e.g., pancreas, liver, ovary). This information helps guide doctors toward the most appropriate follow-up diagnostic tests, such as imaging (CT or PET scans) or biopsies, to confirm the presence and location of the cancer.
• Complementing Existing Screening: MCED tests are not intended to replace existing, proven screening methods like mammograms or colonoscopies. Instead, they are designed to be a complementary tool that screens for a broader range of cancers, particularly those that currently have no recommended screening tests.

The MCED tests that are available and under development:

• Galleri from Grail

It is important to note that while promising, MCED tests are still an emerging technology. Their widespread use is currently under evaluation in large-scale clinical trials to confirm their effectiveness in reducing cancer mortality and to address potential harms like false-positive results, which can lead to unnecessary follow-up procedures and patient anxiety.